A Study of Ruxolitinib in Patients With Graft-Versus Host Disease

ConditionGraft-Versus-Host Disease

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age0+

SponsorNovartis Pharmaceuticals

About this trial

This study aims to evaluate the safety and effectiveness of Jakavi® (ruxolitinib) in patients with acute graft-versus host disease (GVHD) and chronic GVHD in clinical practice.

Eligibility criteria

Qualifiers

Patients with acute and chronic GVHD

Patients treated with ruxolitinib

Disqualifiers

None

Trial design

Treatments tested in this trial

Not listed

Trial groups

395 Participants

are grouped into 1 trial group

Sponsors and collaborators

Novartis Pharmaceuticals

Lead sponsor

Source ClinicalTrials.gov